<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Addiction</journal-id><journal-id journal-id-type="iso-abbrev">Addiction</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Addiction (Abingdon, England)</journal-title></journal-title-group><issn pub-type="ppub">0965-2140</issn><issn pub-type="epub">1360-0443</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7263736</article-id><article-id pub-id-type="pmcid-ver">PMC7263736.1</article-id><article-id pub-id-type="pmcaid">7263736</article-id><article-id pub-id-type="pmcaiid">7263736</article-id><article-id pub-id-type="manuscript-id">NIHMS1064939</article-id><article-id pub-id-type="pmid">31944486</article-id><article-id pub-id-type="doi">10.1111/add.14940</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1064939</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1064939</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of Opioid Dose Escalation on the Development of Substance Use Disorders, Accidents, Self-Inflicted Injuries, Opioid Overdoses, and Alcohol and Non-Opioid Drug-Related Overdoses: A Retrospective Cohort Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hayes</surname><given-names initials="CJ">Corey J.</given-names></name><degrees>PharmD, PhD, MPH</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krebs</surname><given-names initials="EE">Erin E.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hudson</surname><given-names initials="T">Teresa</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brown</surname><given-names initials="J">Joshua</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="C">Chenghui</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Martin</surname><given-names initials="BC">Bradley C.</given-names></name><degrees>PharmD, PhD</degrees><xref ref-type="aff" rid="A6">6</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Health Services Research, College of Medicine,
University of Arkansas for Medical Sciences, 4301 West Markham, Slot 755 Little
Rock, AR 72205</aff><aff id="A2"><label>2</label>Center for Mental Healthcare and Outcomes Research, Central
Arkansas Veterans Healthcare System, 4301 West Markham, Slot 755 Little Rock, AR
72205</aff><aff id="A3"><label>3</label>Center for Care Delivery and Outcomes Research, Minneapolis
VA Healthcare System, 1 Veterans Dr, Minneapolis, MN 55417</aff><aff id="A4"><label>4</label>Department of Medicine, University of Minnesota Medical
School, 1 Veterans Dr, Minneapolis, MN 55417</aff><aff id="A5"><label>5</label>Center for Drug Evaluation and Safety, Department of
Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, 1225
Center Drive HPNP #3334 Gainesville, FL 32610</aff><aff id="A6"><label>6</label>Division of Pharmaceutical Evaluation and Policy, College
of Pharmacy, University of Arkansas for Medical Sciences, 4301 West Markham, Slot
522 Little Rock, AR 72205</aff><author-notes><corresp id="CR1"><label>*</label>Corresponding Author
<email>bmartin@uams.edu</email>, Phone: (501) 603-1992 | Fax: (501)
686-5156</corresp><fn fn-type="COI-statement" id="FN2"><p id="P42"><bold>Conflicts of Interest:</bold> Dr. Martin receives royalties from
TrestleTree LLC for the commercialization of an opioid risk prediction tool,
which is unrelated to the current study. Dr. Li is a paid consultant for
eMaxHealth Systems for unrelated projects.</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><volume>115</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">358682</issue-id><fpage>1098</fpage><lpage>1112</lpage><pub-history><event event-type="nihms-submitted"><date><day>09</day><month>01</month><year>2020</year></date></event><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>06</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-16 15:25:14.020"><day>16</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1064939.pdf"/><abstract id="ABS1"><sec id="S1"><title>Aim:</title><p id="P1">To understand the potential harmful effects of dose escalation among
patients with chronic, non-cancer pain (CNCP) on chronic opioid therapy.</p></sec><sec id="S2"><title>Design:</title><p id="P2">Retrospective cohort study</p></sec><sec id="S3"><title>Setting:</title><p id="P3">United States Veterans Healthcare Administration</p></sec><sec id="S4"><title>Participants:</title><p id="P4">Veterans with CNCP and on chronic opioid therapy were identified
using data from fiscal years 2008&#8211;2015. The Veteran sample was
approximately 90% male and 70% white..</p></sec><sec id="S5"><title>Measurements:</title><p id="P5">Dose escalators (increase of &#707;20% average morphine milligram
equivalent (MME) daily dose) were compared with dose maintainers (change of
&#177;20% average MME daily dose). A composite measure of subsequent
substance use disorders (SUDs: opioid, non-opioid, and alcohol use
disorders) and opioid-related adverse outcomes (AOs: accidents resulting in
wounds/injuries, opioid-related and alcohol and non-opioid
medication-related accidents and overdoses, self-inflicted injuries) as well
as the individual SUDs and AOs was examined. The primary analyses were
conducted among a 1:1 matched sample of escalators and maintainers matched
on propensity score and index date. Propensity scores were generated using
demographic characteristics, medical comorbidities, medication and
healthcare utilization characteristics. Subgroup analyses were conducted by
quartile of the propensity score. Sensitivity analyses were conducted using
adjusted logistic regression, logistic regression using stabilized inverse
probability of treatment weighting (SIPTW), and instrumental variable (IV)
models using geographic variation in opioid dose escalation as the IV.</p></sec><sec id="S6"><title>Findings:</title><p id="P6">There were 32,420 maintainers and 20,767 escalators resulting in
19,358(93.2%) matched pairs. Composite AOs (OR=1.31,95%CI:1.23,1.40),
composite SUDs (OR=1.31,95%CI:1.22,1.41), and individual SUD and AO subtypes
were higher among dose escalators except for opioid-related accidents and
overdoses and violence-related injuries. Subgroup analyses within the
propensity score quartiles found similar results. Sensitivity analyses with
the adjusted and SIPTW logistic regressions found similar results to the
primary analyses for all outcomes except for opioid-related accidents and
overdoses, which were found to be significantly higher among escalators.
Sensitivity analyses with IV models provided mixed results with SUDs and the
individual types of AOs.</p></sec><sec id="S7"><title>Conclusion:</title><p id="P7">Escalating the opioid dose for those with chronic, non-cancer pain is
likely associated with increased risks of substance use disorder and
opioid-related adverse outcomes.</p></sec></abstract><kwd-group><kwd>opioids</kwd><kwd>dose escalation</kwd><kwd>substance use disorders</kwd><kwd>adverse outcomes</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>